ArticleCancers2022

Comparison of Different Tyrosine Kinase Inhibitors for Treatment of Poor Performance Status Patients with EGFR-Mutated Lung Adenocarcinoma.

Chiao-En Wu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.